Pembrolizumab (Keytruda) administered before and after surgery reduced the risk of death by 26% vs placebo in patients with early-stage non–small cell lung cancer (NSCLC), according to 5-year ...

Every year, thousands of families sit in hospital rooms hearing words no one wants to hear: "We have done everything we can." ...

Data from NIAGARA supported the FDA’s approval of neoadjuvant durvalumab in combination with gemcitabine and cisplatin, ...

The perioperative enfortumab vedotin plus pembrolizumab (EV-P) substantially increased the frequency of adverse events (AEs), ...

I'd like to at least give them each a card and small gift, yet each time I set out to write a note, no words can express the ...

Additional efforts are needed to improve quality of life and mitigate suffering in people with sickle cell disease. The field ...

NYU Grossman School of Medicine’s General Surgery Residency in Manhattan provides the skills and expertise needed to ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Excessive Daytime Sleepiness (EDS) in older adults (60+) who undergone non-cardiac surgery is linked to a greater cognitive ...

Community-acquired pneumonia is a major global health challenge that disproportionately affects vulnerable populations, ...

Serplulimab significantly improved event-free survival in gastric cancer, showing potential as a neoadjuvant/adjuvant monotherapy. The combination with chemotherapy achieved a pathologic complete ...